Patents Assigned to Quest Pharmatech, Inc.
-
Patent number: 11773183Abstract: The present document describes an antibody or an antigen-binding fragment that bind to O-glycan mucin-type glycoprotein MUC16 comprising three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable lighy domain CDR (CDR L1, L2 and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16.Type: GrantFiled: April 30, 2019Date of Patent: October 3, 2023Assignee: QUEST PHARMATECH INC.Inventors: Ragupathy Madiyalakan, Michael Hollingsworth, Prakash Radhakrishnan
-
Patent number: 8945566Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.Type: GrantFiled: April 26, 2012Date of Patent: February 3, 2015Assignee: Quest PharmaTech, Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus
-
Patent number: 8916205Abstract: Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.Type: GrantFiled: August 11, 2011Date of Patent: December 23, 2014Assignee: Quest Pharmatech Inc.Inventors: Azita Haddadi, Ragupathy Madiyalakan, Thomas Woo
-
Patent number: 8758725Abstract: The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.Type: GrantFiled: March 11, 2013Date of Patent: June 24, 2014Assignee: Quest Pharmatech Inc.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Publication number: 20140170229Abstract: Biodegradable polymeric nanoparticles comprising an inner core formed of a photodynamic agent capable of being activated to generate cytotoxic singlet oxygen are prepared. These nanoparticles have anti-cell proliferation activity and are useful in treating both cancerous and non-cancerous conditions including actinic keratosis, psoriasis and acne vulgaris. Preferably, the photodynamic agent is a hypocrellin B derivative while the polymeric nanoparticle comprises polyglycolic acid, polylactic acid or poly(lactide-co-glycolide). Hypocrellin-comprising nanoparticles are demonstrated to be activated by light or hydrogen peroxide.Type: ApplicationFiled: August 11, 2011Publication date: June 19, 2014Applicant: Quest Pharmatech Inc.Inventors: Azita Haddadi, Ragupathy Madiyalakan, Thomas Woo
-
Patent number: 8747811Abstract: The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.Type: GrantFiled: August 28, 2013Date of Patent: June 10, 2014Assignee: Quest Pharmatech Inc.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Publication number: 20140072512Abstract: The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.Type: ApplicationFiled: August 28, 2013Publication date: March 13, 2014Applicant: Quest Pharmatech, Inc.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Patent number: 8506931Abstract: The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.Type: GrantFiled: July 28, 2006Date of Patent: August 13, 2013Assignee: Quest Pharmatech Inc.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Patent number: 8038994Abstract: Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.Type: GrantFiled: April 26, 2004Date of Patent: October 18, 2011Assignee: Quest Pharmatech Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus, Antoine A. Noujaim, Ragupathy Madiyalakan
-
Publication number: 20100262115Abstract: The present invention is directed to nanoparticles comprising a cancer therapeutic, pharmaceutical compositions comprising same, and methods for using same for drug delivery and ultrasound or light-based treatment of cancer.Type: ApplicationFiled: April 7, 2010Publication date: October 14, 2010Applicants: INTELLIGENTNANO INC., QUEST PHARMATECH INC.Inventors: Ragupathy MADIYALAKAN, James XING, Thomas WOO, Eric SWANSON
-
Publication number: 20100047178Abstract: The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and/or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.Type: ApplicationFiled: July 28, 2006Publication date: February 25, 2010Applicant: QUEST PHARMATECH INC.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Patent number: 7659244Abstract: The present invention relates to new rapamycin derivatives for the inhibition of cell proliferation. The compounds can advantageously target two proteins in dividing cells and interfere with cell cycle. There is thus provided derivatives of rapamycin in which the 42 position of rapamycin is linked to an amino acid or a peptide through a carbamate ester linkage. These rapamycin derivatives can be synthesized by reacting 42-O-(4-Nitrophenoxycarbonyl) rapamycin and an amino acid or a free amino peptide under basic conditions. These rapamycin derivatives can be used to inhibit the cell cycle and are therefore useful for treating cell proliferation disorders.Type: GrantFiled: November 3, 2004Date of Patent: February 9, 2010Assignee: Quest Pharmatech, Inc.Inventors: Sanjay K. Sharma, Thomas Woo, Selvaraj Naicker
-
Publication number: 20090204057Abstract: The present invention relates to a photodynamic therapy method and uses thereof for treating an individual in need thereof, comprising administering a photosensitizer to an individual and activating the photosensitizer with a chemiluminescent light source, and/or a light-emitting diode light source, wherein the light source is in dermal contact with the individual. The present invention also relates to a device for photodynamic therapy comprising a permeable reservoir, for containing a photosensitizer formulation for skin application, the device is adapted to deliver the photosensitizer to the individual. The present invention also relates to a device for photodynamic therapy, comprising a permeable reservoir for containing a photosensitizer formulation for skin application and a light source.Type: ApplicationFiled: July 17, 2007Publication date: August 13, 2009Applicant: QUEST PHARMATECH INC.Inventors: Thomas Woo, Gerald George Miller, Ragupathy Madiyalakan